[EN] TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME [FR] COMPOSÉS DE TÉTRAHYDROPYRAZOLO-PYRAZINYLE-DIHYDROIMIDAZOLONE OU DE TÉTRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE ET LEURS PROCÉDÉS D'UTILISATION
Direct functionalization of the 3-oxygenated isothiazole heteroaromatic parental system has not yet been reported in the literature. Here, we report the first regioselective lithiation of the 5-position of 3-(benzyloxy)isothiazole (4) using LDA in diethyl ether. The versatility of the methodology was explored by quenching with a variety of electrophiles to give the desired products 7a,b,d-g in 54-68%
[EN] TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE TÉTRAHYDROPYRAZOLO-PYRAZINYLE-DIHYDROIMIDAZOLONE OU DE TÉTRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE ET LEURS PROCÉDÉS D'UTILISATION
申请人:ECCOGENE SHANGHAI CO LTD
公开号:WO2022017338A1
公开(公告)日:2022-01-27
The application relates to a compound of Formula (I) : or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.